Lemmy, thanks for sharing the plot of the pps trend for the last dozen years. It does provide an interesting story back drop. Working within those bands bracketing highs and lows, lie the status of PPHM technology development towards commercialization.
There was Oncolym, which preceded my investment entry into TCLN, followed by Cotara and Tumor Necrosis Therapy. Then along came Tarvacin, now Bavituximab. Recognizing it can take ten years for a promising drug candidate to make it through trials into FDA approvals and considering how much money is needed to invest in same, there is that interesting deflection in formation since January of 2012, when it became apparent that Bavi was showing exceptional results in the Phase 2 NSCLC trial, despite the clear evidence of dose switching. Now long investors are seeing tech reinforcement with FDA approval of the PPHM Phase 3 trial design, PPHM announced trial start, FDA granting of Fast Track Status and an S3 that suggests a path by which PPHM can fund all this, with or without a partner. That is quite a contrast to how things played out years back when investors were hopeful for China news and the sobering realization came that Cancer Therapeutics Laboratories may have gone rogue and the Epstein lawsuit was required.
I observe now that it is very nice for those who have made a long investment with recognition of how long it can take for a drug like Bavituximab and the anti-PS platform to make its way to approval. Things look hopeful in a way that I have not seen since my initial TCLN/PPHM investment. And, due to my cost averaging and accumulation investment strategy, I hold about five hundred times more shares than my first exploratory investment that posted with a pre split pps basis of about $35 at an average cost basis that might even allow me a profitable outcome if the PPHM business plan delivers this time.
Good luck with your PPHM investment.
Best wishes and IMO.
KT
